Psychedelics and fNIRS neuroimaging: exploring new opportunities
Felix Scholkmann, Franz X. Vollenweider
Neurophotonics December 2, 2022 DOI: 10.1117/1.nph.10.1.013506 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Functional near-infrared spectroscopy Popularity Exploit Functional neuroimaging Cognitive psychology Data science Cognitive science |
| Citations | 10 |
| Key findings | Functional near-infrared spectroscopy has great potential for exploring psychedelic-induced brain activity changes, and the current momentum in both fields makes it an opportune time to establish fNIRS in psychedelic research. |
Abstract
In this Outlook paper, we explain to the optical neuroimaging community as well as the psychedelic research community the great potential of using optical neuroimaging with functional near-infrared spectroscopy (fNIRS) to further explore the changes in brain activity induced by psychedelics. We explain why we believe now is the time to exploit the momentum of the current resurgence of research on the effects of psychedelics and the momentum of the increasing progress and popularity of the fNIRS technique to establish fNIRS in psychedelic research. With this article, we hope to contribute to this development.
Citations in the library
Cited by 5
- Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS. Scientific Reports July 19, 2023
- Psychedelics, entactogens and psychoplastogens for depression and related disorders British Journal of Pharmacology June 15, 2025
- Cortical Correlates of Psychedelic-Induced Shaking Behavior Revealed by Voltage Imaging International Journal of Molecular Sciences May 30, 2023
- Acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans: A TD-fNIRS neuroimaging study bioRxiv (Cold Spring Harbor Laboratory) January 9, 2023
- On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders. May 23, 2024
Cites 74
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 69 more in the library